CTOs on the Move

Frontida BioPharm

www.frontidabiopharm.com

 
Frontida BioPharm is a Minority-Owned Contract Development & Manufacturing Organization. We work collaboratively with our clients to bring new and improved products to the pharmaceutical market. By leveraging our team`s vast knowledge and experience we are able to improve the success of our client`s business and product development efforts. Frontida was launched by founding management team members of Frontage Laboratories. Having 15 years of success in the business Frontage remains a thriving CRO that has become a full service R&D organization located in PA, NJ, and China. With strong record of FDA compliance and quality service to global pharmaceutical and ...
  • Number of Employees: 250-1000
  • Annual Revenue: $50-100 Million

Executives

Name Title Contact Details

Similar Companies

GL Sciences

GL Sciences is a Torrance, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Molecular NeuroImaging

Molecular NeuroImaging is a New Haven, CT-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Banner Pharmacaps Inc

Banner is a global gelatin-based drug delivery and specialty pharmaceutical company. We are committed to researching, developing and producing unique oral dosage forms for the Pharmaceutical Health Care Industry. Through our innovative technologies and

Cebert Pharmaceuticals

Cebert Pharmaceuticals is a Birmingham, AL-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Pharvaris

Pharvaris is a clinical-stage company focused on bringing oral bradykinin-B2-receptor antagonists to patients. By targeting this clinically proven therapeutic target with novel small molecules, the Pharvaris team is advancing new alternatives to injected therapies for all sub-types of HAE and other bradykinin-mediated diseases. The company brings together executives with a breadth of expertise across pharmaceutical development and rare disorders, including HAE. The company reunites the core team responsible for the discovery and approval of the HAE treatment icatibant. With novel small molecules, we have identified and are advancing potent, orally available compounds targeting this clinically proven therapeutic target.